Edwards Lifesciences Corp (NYSE:EW) Shares Purchased by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. increased its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,090 shares of the medical research company’s stock after purchasing an additional 191 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Edwards Lifesciences were worth $1,421,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Manchester Financial Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth $26,000. Savior LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. Quest Capital Management Inc. ADV purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $28,000. Usca Ria LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $34,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $50,000. Hedge funds and other institutional investors own 80.62% of the company’s stock.

A number of research analysts have recently weighed in on EW shares. Canaccord Genuity restated a “buy” rating and issued a $260.00 price target on shares of Edwards Lifesciences in a research report on Friday, December 6th. Jefferies Financial Group raised their price target on Edwards Lifesciences from $255.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Wells Fargo & Co raised their price target on Edwards Lifesciences from $262.00 to $270.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. Raymond James raised their price target on Edwards Lifesciences from $255.00 to $263.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. Finally, UBS Group raised their price target on Edwards Lifesciences from $250.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $239.42.

In related news, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $238.79, for a total transaction of $5,456,351.50. Following the completion of the sale, the chief executive officer now owns 95,770 shares in the company, valued at approximately $22,868,918.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Catherine M. Szyman sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $242.14, for a total value of $605,350.00. Following the sale, the vice president now owns 19,605 shares of the company’s stock, valued at approximately $4,747,154.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 164,241 shares of company stock valued at $38,597,230. 1.63% of the stock is currently owned by company insiders.

Edwards Lifesciences stock opened at $228.92 on Tuesday. The stock has a market cap of $48.06 billion, a PE ratio of 62.72, a P/E/G ratio of 2.53 and a beta of 0.77. The stock has a 50-day moving average price of $234.32 and a 200 day moving average price of $225.87. Edwards Lifesciences Corp has a 52 week low of $163.08 and a 52 week high of $247.64. The company has a current ratio of 3.53, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Trade War

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.